Evan David Seigerman, BMO managing director, joins 'Fast Money' to discuss Novo sinking on its obesity drug data.

Health-care companies rose, as health insurers and other "middle men" recouped some of their recent losses. UnitedHealth Group, which has become the center of a public debate about health-care policy ...

Signs outside of AMPAC’s 600,000 square-foot facility on Normandy Drive, however, have been changed to reflect the new owners ...

Stocks finished higher on Friday, recovering a portion of the massive losses posted earlier in the week, as the market ...

Europe’s Stoxx 600 clocked its second straight weekly fall on Friday (Dec 20), with the healthcare sector leading losses ...

The Food and Drug Administration expanded the approval of weight loss drug Zepbound to treat obstructive sleep apnea in ...

The agency’s decision expands the use of Zepbound and could potentially pave the way for Eli Lilly to gain broader insurance ...

U.S. stocks are rallying Friday to more than halve their losses in what had been one of their worst weeks of the year.

An experimental Novo Nordisk anti-obesity treatment helped patients lose less than a quarter of their bodyweight in a new ...

Novo Nordisk’s latest attempt in weight loss, a combination drug called CagriSema, matched the bar set by Lilly’s currently ...

U.S. stocks are rallying to more than halve their losses in what had been one of their worst weeks of the year. The S&P 500 ...

The state's fastest-growing such health care facility will debut 30,000 square feet of brand-new space to serve community ...